Contineum Therapeutics, Inc.

Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.

Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).

Contineum Therapeutics has commenced patient dosing in a Phase 1b clinical trial evaluating PIPE-791, an LPA1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms.